These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28710943)

  • 1. Survival after recurrence of stage I-III breast, colorectal, or lung cancer.
    Hassett MJ; Uno H; Cronin AM; Carroll NM; Hornbrook MC; Fishman P; Ritzwoller DP
    Cancer Epidemiol; 2017 Aug; 49():186-194. PubMed ID: 28710943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.
    Hassett MJ; Ritzwoller DP; Taback N; Carroll N; Cronin AM; Ting GV; Schrag D; Warren JL; Hornbrook MC; Weeks JC
    Med Care; 2014 Oct; 52(10):e65-73. PubMed ID: 23222531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis.
    Ritzwoller DP; Fishman PA; Banegas MP; Carroll NM; O'Keeffe-Rosetti M; Cronin AM; Uno H; Hornbrook MC; Hassett MJ
    Health Serv Res; 2018 Dec; 53(6):5106-5128. PubMed ID: 30043542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
    Moore S; Leung B; Wu J; Ho C
    Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer.
    Banegas MP; Hassett MJ; Keast EM; Carroll NM; O'Keeffe-Rosetti M; Fishman PA; Uno H; Hornbrook MC; Ritzwoller DP
    Value Health; 2022 Jan; 25(1):69-76. PubMed ID: 35031101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival differences among women with de novo stage IV and relapsed breast cancer.
    Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
    Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
    Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
    Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women.
    Milano MT; Strawderman RL; Venigalla S; Ng K; Travis LB
    J Thorac Oncol; 2014 Aug; 9(8):1081-90. PubMed ID: 25157761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Survival for Patients Diagnosed With Breast, Colorectal, and Lung Cancer in an Integrated System.
    Hahn EE; Ritzwoller DP; Munoz-Plaza CE; Gander J; Kushi LH; McMullen C; Oshiro C; Roblin DW; Wernli KJ; Staab J
    Perm J; 2023 Dec; 27(4):129-135. PubMed ID: 37724894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality rates by stage-at-diagnosis.
    Clinton K
    Semin Surg Oncol; 1994; 10(1):7-11. PubMed ID: 8115787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in the survival improvement of recurrent breast cancer.
    Anan K; Mitsuyama S; Koga K; Tanabe R; Saimura M; Tanabe Y; Watanabe M; Suehara N; Matsunaga H; Nishihara K; Abe Y; Nakano T; Tamae K; Ono M; Toyoshima S
    Breast Cancer; 2010; 17(1):48-55. PubMed ID: 19350357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Dal Maso L; Toffolutti F; De Paoli A; Giudici F; Francisci S; Bucchi L; Zorzi M; Fusco M; Caldarella A; Rossi S; De Angelis R; Botta L; Ravaioli A; Casella C; Musolino A; Vitale MF; Mangone L; Fanetti AC; Carpin E; Burgio Lo Monaco MG; Migliore E; Gambino ML; Ferrante M; Stracci F; Gasparotti C; Carrozzi G; Cavallo R; Mazzucco W; Ballotari P; Ferretti S; Sampietro G; Rizzello RV; Boschetti L; Cascone G; Mian M; Pesce MT; Piras D; Galasso R; Bella F; Seghini P; Pinna P; Crocetti E; Serraino D; Guzzinati S;
    Int J Cancer; 2024 Jul; 155(2):270-281. PubMed ID: 38520231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Malmgren J; Hurlbert M; Atwood M; Kaplan HG
    Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    Snyder RA; Hu CY; Cuddy A; Francescatti AB; Schumacher JR; Van Loon K; You YN; Kozower BD; Greenberg CC; Schrag D; Venook A; McKellar D; Winchester DP; Chang GJ;
    JAMA; 2018 May; 319(20):2104-2115. PubMed ID: 29800181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
    Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
    Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.